Risques de Covid-19 grave associés à certains médicaments

Dossier thématique sur la mobilisation d'EPI-PHARE pendant la pandémie COVID-19 : risques de Covid-19 grave associés à certains médicaments
  • Utilisation au long cours d’antipaludéens de synthèse et risque de survenue de formes graves ou létales de la COVID-19. 30 juin 2020. [lien]


Articles publiés dans des revues à Comité de lecture
  • Kolla, E., Weill, A., Desplas, D., Semenzato, L., Zureik, M., & Grimaldi, L. (2022). Does Measles, Mumps, and Rubella (MMR) Vaccination Protect against COVID-19 Outcomes : A Nationwide Cohort Study. Vaccines, 10(11), Art. 11. [lien]
  • Bouillon, K. et al. (2022) ‘Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID‐19: A Nationwide Matched Population‐Based Cohort Study’, Journal of the American Heart Association, p. e023357. [lien]
  • Botton, J. et al. (2022) ‘No association of low-dose aspirin with severe COVID-19 in France: A cohort of 31.1 million people without cardiovascular disease’, Research and Practice in Thrombosis and Haemostasis, 6(4), p. e12743. [lien]
  • Semenzato Laura et al. (2021) ‘Antihypertensive Drugs and COVID-19 Risk’, Hypertension, 77(3), pp. 833–842. [lien]
  • Penso, L. et al. (2021) ‘Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1,326,312 patients in France’, British Journal of Dermatology, 186(1), pp.59-68. [lien]
  • Meyer, A. et al. (2021) ‘Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study’, Alimentary Pharmacology & Therapeutics, 54(2), pp. 160–166. [lien]
  • Sbidian, E. et al. (2020) ‘Comment on “Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19” by Konig et al. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed individuals in France’, Annals of the Rheumatic Diseases. . [lien]